特发性肺纤维化(IPF)市场：按药物、给药途径、分销渠道、区域-规模、份额、前景和机会分析，2023-2030年

特发性肺纤维化(IPF) 是一种原因不明的慢性疾病，主要影响老年人的肺部，与间质性肺炎(UIP) 的常见组织病理学和/或放射学模式相关。是一种特殊形式的进行性肺纤维化。纤维化间质性肺炎。 IPF 的诊断需要排除其他形式的间质性肺疾病，包括特发性间质性肺炎 (IIP) 和与环境暴露、药物和结缔组织疾病相关的间质性肺疾病 (ILD)。

市场动态

特发性肺纤维化（IPF）患病率的增加预计将推动市场增长。 例如，2021年7月，根据美国国家医学图书馆发布的报告，2020年特发性肺纤维化（IPF）的患病率为全球每10万人中13-20人。 2020年，美国将有约10万人被确诊，而每年新增确诊人数为3万至4万人。

国家生物技术信息中心发布的一份报告发现，2021年印度特发性肺纤维化（IPF）的患病率约为13.7%。

此外，特发性肺纤维化 (IPF) 的患病率日益增加，促使主要市场参与者专注于新产品的推出，预计这将在预测期内推动市场增长。Masu。 例如，2022年5月，全球仿製药和生物仿製药领导者山德士宣布将与生物技术公司基因泰克旗下的Esbriett竞争特发性肺纤维化（IPF）患者的治疗，并宣布在美国上市□非尼酮，第一个AB级（抗体）（完全可替代）。 这种口服药是通过专门的药房给患者开的。

本研究的主要特点

• 本报告对全球特发性肺纤维化(IPF) 市场进行了深入分析，揭示了以2022 年为基准年的预测期（2023-2030 年）的市场规模和復合年增长率(CAGR% ) .) 已发布。
• 它揭示了各个细分市场的潜在收入机会，并概述了该市场有吸引力的投资主张矩阵。
• 它还提供了有关市场驱动因素、限制因素、机遇、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
• 它根据以下参数介绍了全球特发性肺纤维化 (IPF) 市场的领先企业 - 公司亮点、产品组合、主要亮点、财务业绩、战略。本研究涵盖的主要公司包括Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical（India）Pvt Ltd, Sandoz International GmbH（Novartis）, and Algernon Pharmaceuticals Inc.等。
• 从本报告中获得的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。 .
• 《全球特发性肺纤维化 (IPF) 市场报告》面向该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
• 利益相关者可以通过用于分析全球特发性肺纤维化 (IPF) 市场的各种策略矩阵来促进决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写

第 2 章市场展望

• 报告概述
  • 市场定义和范围
• 执行摘要
• 连贯的机会地图 (COM)

第 3 章市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 市场吸引力分析
  • 市场机会
  • 产品发布
  • 合併、收购与合作
  • 监管指南和合规性
  • 主要进展
  • 市场趋势
  • PEST分析
  • 流行病学
  • 波特的分析
  • 监管场景
  • 品牌分析
  • 价格分析
  • 管道分析

第 4 章全球特发性肺纤维化 (IPF) 市场 - 冠状病毒 (COVID-19) 大流行的影响

• 经济影响
• COVID-19 的流行病学特征
• 对供需的影响

第 5 章 2017-2030 年特发性肺纤维化 (IPF) 全球市场（按代理商）

• □非尼酮
• 尼达尼布
• 其他（干扰素 gamma-1b、其他）

第 6 章按给药途径划分的全球特发性肺纤维化 (IPF) 市场，2017-2030 年

• 口服剂
• 非口服药

第 7 章 2017-2030 年特发性肺纤维化 (IPF) 全球市场（按分销渠道）

• 医院药房
• 零售药店
• 网上药店

第 8 章2017-2030 年全球特发性肺纤维化 (IPF) 市场（按地区）

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 欧洲其他地区
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 亚太地区其他地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第 9 章竞争格局

• Genentech, Inc.
• Boehringer Ingelheim International GmbH.
• Avalyn Pharma, Inc.
• AstraZeneca
• Blade Therapeutics
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche
• FibroGen, Inc.
• Galapagos NV
• MediciNova, Inc.
• Merck & Co., Inc.
• Promedior, Inc.
• Prometic Life Sciences Inc.
• Daewoong Pharmaceutical（India）Pvt Ltd
• Sandoz International GmbH（Novartis）
• Algernon Pharmaceuticals Inc.

第 10 章

• 调查方法
• 关于出版商

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.

Market Dynamics

Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.

According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.

Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech's, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies

Key features of the study:

• This report provides in-depth analysis of the global Idiopathic pulmonary fibrosis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market

Detailed Segmentation:

• Global Idiopathic pulmonary fibrosis market, By Drug:
  • Pirfenidone
  • Nintedanib
  • Others (Interferon gamma-1b and Others)
• Global Idiopathic pulmonary fibrosis market, By Route of Administration:
  • Oral
  • Parenteral
• Global Idiopathic pulmonary fibrosis market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Idiopathic pulmonary fibrosis market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Genentech, Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim International GmbH
  • Avalyn Pharma, Inc.
  • AstraZeneca
  • Blade Therapeutics
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Hoffmann-La Roche
  • FibroGen, Inc.
  • Galapagos NV
  • MediciNova, Inc.
  • Merck & Co., Inc.
  • Promedior, Inc.
  • Prometic Life Sciences Inc.
  • Daewoong Pharmaceutical (India) Pvt Ltd
  • Sandoz International GmbH (Novartis)
  • Algernon Pharmaceuticals Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
  • Product Launches
  • Merger, Acquisition, Collaboration
  • Regulatory Guideline and Compliances
  • Key Developments
  • Market Trends
  • PEST Analysis
  • Epidemiology
  • PORTER's Analysis
  • Regulatory Scenario
  • Brand Analysis
  • Pricing Analysis
  • Pipeline Analysis

4. Global Idiopathic Pulmonary Fibrosis Market- Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Pirfenidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Nintedanib
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Interferon gamma-1b and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Genentech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim International GmbH.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Avalyn Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Blade Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cipla Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• FibroGen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Galapagos NV
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• MediciNova, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Promedior, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prometic Life Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Daewoong Pharmaceutical (India) Pvt Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sandoz International GmbH (Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Algernon Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us